// App-Quantinova.ai

: Development of a Data Portal for Aggregation and Analysis of Genomics Data in Familial Platelet Disorder with Predisposition to Myeloid Malignancy - the RUNX1.DB

Researchers

Presenter

  • Anna L. Brown

Principal Investigators

  • David Lawrence

  • Paul Wang

  • Peer Arts

  • Nicolas Duployez

  • Jane Churpek

  • Kiran Tawana

  • Erin Degelman

  • Georges Natsoulis

  • Monica L. Guzman

  • Mrinal M. Patnaik

  • Akiko Shimamura

  • Alan B. Cantor

  • Tim Ripperger

  • Brigitte Schlegelberger

  • Doris Steinemann

  • Courtney D. DiNardo

  • Cristina Mecucci

  • Elvira DRP Velloso

  • Fabio PS Santos

  • Marcela CA Silva

  • Uma Borate

  • Shannon K. McWeeney

  • Grzegorz Nalepa

  • Susanne Ragg

  • Erika Mijin Kwon

  • Anupriya Agarwal

  • Stephen Langabeer

  • Jeffery M. Klco

  • Jun J. Yang

  • Cecily Forsyth

  • Sally Mapp

  • Helen Mar Fan

  • Lesley Rawlings

  • Rachel Susman

  • Sue Morgan

  • Andrew H Wei

  • Inderjeet Dokal

  • Tom Vulliamy

  • Devendra K Hiwase

  • Deepak Singhal

  • Susan Branford

  • Elli Papaemmanuil

  • Jean Soulier

  • Stefan Frhling

  • Alwin Kramer

  • Guy Sauvageau

  • Neil Morgan

  • Carolyn Owen

  • Csaba Bdr

  • Jude Fitzgibbon

  • Hugh Y. Rienhoff

  • Mineo Kurokawa

  • Lucy Godley

  • Claude Preudhomme

  • Paul P Liu

  • Nicola Poplawski

  • Christopher N. Hahn

  • Hamish S. Scott

Medical Centers

  • Molecular Oncology, Centre For Cancer Biology, SA Pathology/IMVS, Adelaide, Australia

  • Molecular Oncology, Centre for Cancer Biology, SA Pathology and University of South Australia, Adelaide, Australia

  • ACRF Cancer genomics facility, Centre for Cancer Biology, SA Pathology, Adelaide, Australia

  • Centre for Cancer Biology, SA Pathology, Adelaide, Australia

  • Centre for Cancer Biology, SA Pathology, University of Adelaide, Adelaide, Australia

  • Cancer Research Institute, INSERM Unité Mixte de Recherche (UMR)-S 1172, F-59000 Lille, CHU Lille, Laboratory of Hematology, F-59000 Lille, Lille, France

  • Section of Hematology/Oncology, University of Chicago, Chicago, IL

  • Barts Cancer Institute, London, GBR

  • Cumming School of Medicine / Charbonneau Cancer Research Insitute, University of Calgary, Calgary, Canada

  • Imago Biosciences, Inc., San Carlos, CA

  • Division of Hematology and Oncology, Weill Cornell Medical College Division of Hematology/Oncology, New York, NY

  • Division of Medical Oncology, Mayo Clinic, Rochester, MN

  • Dana-Farber Cancer Institute/Boston Children's Cancer and Blood Disorder Center, Boston, MA

  • Department of Pediatric Oncology, Boston Childrens Hospital, Dana-Farber Cancer Institute, Harvard Medical School, HHMI, Boston, MA

  • Institute of Human Genetics, Hannover Medical School, Hannover, Germany

  • Department of Human Genetics, Munich, Germany

  • Department of Genetics, UT MD Anderson Cancer Center, Houston, TX

  • University of Perugia, Perugia, ITA

  • Clinical Hospital of University of Sando Paulo Medical School, Sando Paulo, Brazil

  • Hospital Israelita Albert Einstein, Sao Paulo, Brazil

  • University of Sao Paulo, Sao Paulo, Brazil

  • Knight Cancer Institute, Oregon Health and Science University, Portland, OR

  • Knight Cancer Institute, Division of Bioinformatics and Computational Biology, Oregon Health and Science University, Portland, OR

  • Department of Urology, Indiana University School of Medicine, Indianapolis, IN

  • Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN

  • Oncogenesis and Development Section, National Human Genome Research Institute NHGRI, Bethesda, MD

  • Oregon Health and Science University, Portland, OR

  • Cancer Molecular Diagnostics, St. James's University Hospital, Dublin, Ireland

  • St. Jude Children's Research Hospital, Memphis, TN

  • Department of Pharmaceutical Sciences, St Jude Children's Research Hospital, Memphis, TN

  • Wyong Hospital, Wyong, Australia

  • Princess Alexandra Hospital, Brisbane, Australia

  • Genetic Health Queensland, Brisbane, Australia

  • University of South Australia, Adelaide, Australia

  • Queensland Health, Brisbane, Australia

  • ALFRED HOSPITAL, Melbourne, AUS

  • Department of Clinical Haematology, Austin Hospital, Melbourne, Australia

  • Barts and Queen Mary's University London, London, GBR

  • Queen Mary College of London, London, GBR

  • Department of Haematology,Royal Adelaide Hospital and SA Pathology,Adelaide,Australia

  • Royal Adelaide Hospital, Adelaide, Australia

  • Molecular Pathology, Centre for Cancer Biology /SA Pathology RAH site, Adelaide, Australia

  • Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY

  • Hematology Laboratory and INSERM U944, Hopital Saint-Louis Centre Hayem 2ETG, Paris, France

  • Department of Translational Oncology, National Center for Tumor Diseases (NCT) Heidelberg and German Cancer Research Center (DKFZ), Heidelberg, Germany

  • Klinische Kooperationseinheit Molekulare Hämatologie/Onkologie, Medizinische Klinik V, Universität Heidelberg and German Cancer Research Center (DKFZ), Heidelberg, Germany

  • The Leucegene Project at the Institute for Research in Immunology and Cancer (IRIC), Montréal, QC, Canada, Montréal, Canada

  • Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, United Kingdom

  • Medicine and Oncology, University of Calgary, Calgary, AB, Canada

  • MTA-SE Momentum Molecular Oncohematology Research Group, First Department of Pathology and Experimental Cancer Research,Semmelweis University,Budapest,Hungary

  • Bart's Cancer Institute, London, United Kingdom

  • Imago Biosciences, San Francisco

  • Department of Cell Therapy and Transplantation Medicine, The University of Tokyo Hospital, Tokyo, Japan

  • Centre de Biologie-Pathologie, Centre Hospitalier Universitaire de Lille, Lille, France

  • South Australian Clinical Genetics Service, Adelaide, Australia

  • Department of Genetics and Molecular Pathology, SA Pathology, Adelaide, Australia

  • Centre for Cancer Biology, SA Pathology, University of Adelaide, Adelaide, Australia

Locations

  • Australia

  • France

  • United States

  • Canada

  • Germany

  • Brazil

  • Ireland

  • United Kingdom

  • Hungary

  • Japan

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • ETV6-RUNX1

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved